Latest news with #EmcurePharmaceuticals
Fashion Value Chain
3 days ago
- Business
- Fashion Value Chain
Emcutix Unveils Flawlizo Range for Rapid Acne Relief
Emcutix Biopharmaceuticals Ltd., a subsidiary of Emcure Pharmaceuticals, has entered the anti-acne skincare market with the launch of its Flawlizo Xpert Acne Care range—offering targeted, science-led solutions for fast and effective acne management. The highlight of the consumer range includes: Flawlizo Acne Spot Corrector – a biphasic formulation clinically proven to reduce early breakouts within 3–5 days Flawlizo Acne Care Moisturizing Gel – a non-comedogenic, hydrating solution enriched with natural extracts, designed to nourish acne-prone skin without clogging pores The products are developed to deliver visible results, while maintaining skin barrier integrity and hydration—offering a complete acne care routine that addresses breakout treatment and long-term skin health. In addition to the consumer offerings, the Flawlizo portfolio also includes five prescription-only products featuring Tretinoin, a globally recognized gold-standard acne treatment. These are manufactured at Encube Ethicals, a USFDA-certified facility with one of the largest global capabilities in topical dermatological formulations. Sathya Narayanan, CEO, Emcutix Biopharmaceuticals Ltd., stated: 'Flawlizo reflects our commitment to uniting clinical science with real-world skincare needs. It empowers individuals to manage acne with confidence and care, using safe, effective, and accessible solutions.' This launch reinforces Emcutix's growing footprint in dermatology, spanning prescription, aesthetic, and over-the-counter skincare solutions. The move follows the company's exclusive licensing partnership with WiQo, introducing PRX-PLUS, a non-invasive skin treatment, to the Indian market for the first time.
&w=3840&q=100)
Business Standard
23-05-2025
- Business
- Business Standard
Emcure Pharma hits 10% upper circuit; gains 20% in three days; here's why
Emcure Pharmaceuticals shares were locked in a 10 per cent upper circuit on Friday, May 23, 2025. The stock extended rally for the third consecutive session and gained nearly 20 per cent. The buying on the counter came after the company released its Q4 results. At 12:27 PM, Emcure Pharma share price was up 10 per cent at ₹1,288.65 per share on the BSE. In comparison, the BSE Sensex was up 0.97 per cent at 81,734.05. The market capitalisation of the company stood at ₹24,417.77 crore. The 52-week high of the stock was at ₹1,577.5 per share and the 52-week low of the stock was at ₹890 per share. Emcure Pharmaceutical Q4 profit growth The company released its Q4 results on Thursday, after market hours. In the fourth quarter (Q4FY25) pharma company's net profit stood at ₹197.2 crore as against ₹121 crore, up 62 per cent. Its revenue from operations in Q4 came in at ₹2,116.2 crore as compared to ₹1,771.3 crore a year ago, up 19 per cent. Emcure Pharma dividend The company's board recommended a final dividend of ₹3 per equity share of ₹10 /- (Rupees Ten only) each of the company (at the rate of 30 per cent) for the financial year ended March 31, 2025. Emcure Pharma acquisition The board also approved the incorporation of company arm Emcure Generics Private Limited. "We would like to inform that the board of directors of the company in their meeting held today i.e. May 22, 2025, has inter-alia approved the incorporation of a wholly-owned Subsidiary by the name 'Emcure Generics Private Limited' in Pune, Maharashtra, India," the filing read. About Emcure Pharmaceuticals Emcure Pharma has over 350 brands, five research and development (R&D) centers, and 13 manufacturing facilities established across the country, outside India, it has a wide network across 70 countries. The company's API facilities ensure that the supply chain is vertically integrated providing flexibility over control of manufacturing. The company's core strength and competitive advantage lie in its established presence in all major therapeutic areas including Gynaecology, cardiology, blood-related, oncology, respiratory, CNS & HIV among others. Emcure has launched 6 biologics in the domestic market and RoW markets.
Mint
23-05-2025
- Business
- Mint
Shark Tank's Namita Thappar-backed Emcure Pharma shares surge 20% in two sessions after robust Q4 earnings
Shares of Emcure Pharmaceuticals were locked in the 10 per cent upper circuit at ₹ 1,288.65 on Friday, May 23, as the stock extended its rally to the second straight session. The rally comes on the back of a strong performance for the quarter ended March 2025 (Q4FY25). The stock had already surged nearly 9 per cent in the previous session, taking its total two-day gain to about 20 per cent. As of the March 2025 quarter, Shark Tank judge Namita Vikas Thapar owns 50.71 lakh shares or a 2.68 per cent stake of the firm. Emcure reported a 64 per cent year-on-year (YoY) jump in consolidated net profit to ₹ 189 crore in Q4FY25, compared to ₹ 115 crore in the same quarter last year. The revenue from operations rose 20 per cent YoY to ₹ 2,116 crore, up from ₹ 1,771 crore. Sequentially, the company's net profit grew 26.4 per cent, while revenue increased by 7.8 per cent from the previous quarter's net profit of ₹ 156 crore and revenue of ₹ 1,936 crore. According to Satish Mehta, CEO and Managing Director of Emcure Pharmaceuticals, 'The company delivered a very strong performance in Q4, with all business segments contributing to growth. On the domestic side, we expanded our covered market and built a strong product pipeline. In international markets, we are seeing approvals for our differentiated offerings.' NSE filing by Emcure highlighted strong traction in both domestic and international operations: Domestic business revenue surged 24.8 per cent YoY to ₹ 929 crore, driven by growth in the women's health and cardiology franchises, supported by emerging focus areas like dermatology and OTC products. 929 crore, driven by growth in the women's health and cardiology franchises, supported by emerging focus areas like dermatology and OTC products. International business also expanded, growing 15.6 per cent YoY to ₹ 1,187 crore, led by a 39.3 per cent YoY jump in revenue from the Rest of the World segment to ₹ 481 crore. 1,187 crore, led by a 39.3 per cent YoY jump in revenue from the Rest of the World segment to 481 crore. In Canada, revenue rose 6.2 per cent YoY to ₹ 310 crore, with Mantra—its recent acquisition—now fully integrated. In the European Union, revenue posted a modest 1.7 per cent rise, supported by a recently acquired product portfolio and new regulatory approvals. The company stated that it remains focused on improving margins through new product launches and operating efficiencies, which will be key priorities in FY26. The Board of Directors also recommended a final dividend of ₹ 3 per equity share of face value ₹ 10 each (30 per cent of face value) for the financial year ended March 31, 2025. The dividend is subject to shareholder approval at the upcoming Annual General Meeting (AGM) and will be paid within the regulatory timelines once approved. Emcure's stock has gained nearly 28 per cent from its IPO price of ₹ 1,008, with the company debuting on the bourses in July 2024. Currently, the pharma stock trades 18 per cent below its record high of ₹ 1,577.50, touched in September 2024. However, it has recovered sharply, rising 45 per cent from its 52-week low of ₹ 890, hit in April 2025. In May 2025 alone, the scrip has jumped over 25 per cent, rebounding from a 5 per cent dip in April. Before that, it gained 9 per cent in March, but had declined 20 percent in February and 15 per cent in January, indicating a recent shift in sentiment.
Mint
23-05-2025
- Business
- Mint
Emcure Pharmaceuticals shares surge 20% in two sessions after robust Q4 earnings
Shares of Emcure Pharmaceuticals were locked in a 10 percent upper circuit at ₹ 1,288.65 on Friday, May 23, as the stock extended its rally for a second straight session. The rally comes on the back of a strong performance for the quarter ended March 2025 (Q4FY25). The stock had already surged nearly 9 percent in the previous session, taking its total two-day gain to about 20 percent. As of the March 2025 quarter, Shark Tank judge Namita Vikas Thapar owns 50.71 lakh share or a 2.68 percent stake of the firm. Emcure reported a 64 percent year-on-year (YoY) jump in consolidated net profit to ₹ 189 crore in Q4FY25, compared to ₹ 115 crore in the same quarter last year. The revenue from operations rose 20 percent YoY to ₹ 2,116 crore, up from ₹ 1,771 crore. Sequentially, the company's net profit grew 26.4 percent, while revenue increased by 7.8 percent from the previous quarter's net profit of ₹ 156 crore and revenue of ₹ 1,936 crore. According to Satish Mehta, CEO and Managing Director of Emcure Pharmaceuticals, 'The company delivered a very strong performance in Q4, with all business segments contributing to growth. On the domestic side, we expanded our covered market and built a strong product pipeline. In international markets, we are seeing approvals for our differentiated offerings.' NSE filing by Emcure highlighted strong traction in both domestic and international operations: Domestic business revenue surged 24.8 percent YoY to ₹ 929 crore, driven by growth in the women's health and cardiology franchises, supported by emerging focus areas like dermatology and OTC products. International business also expanded, growing 15.6 percent YoY to ₹ 1,187 crore, led by a 39.3 percent YoY jump in revenue from the Rest of the World segment to ₹ 481 crore. In Canada, revenue rose 6.2 percent YoY to ₹ 310 crore, with Mantra—its recent acquisition—now fully integrated. In the European Union, revenue posted a modest 1.7 percent rise, supported by a recently acquired product portfolio and new regulatory approvals. The company stated that it remains focused on improving margins through new product launches and operating efficiencies, which will be key priorities in FY26. The Board of Directors also recommended a final dividend of ₹ 3 per equity share of face value ₹ 10 each (30 percent of face value) for the financial year ended March 31, 2025. The dividend is subject to shareholder approval at the upcoming Annual General Meeting (AGM), and will be paid within the regulatory timelines once approved. Emcure's stock has gained nearly 28 percent from its IPO price of ₹ 1,008, with the company debuting on the bourses in July 2024. Currently, the pharma stock trades 18 percent below its record high of ₹ 1,577.50, touched in September 2024. However, it has recovered sharply, rising 45 percent from its 52-week low of ₹ 890, hit in April 2025. In May 2025 alone, the scrip has jumped over 25 percent, rebounding from a 5 percent dip in April. Before that, it gained 9 percent in March, but had declined 20 percent in February and 15 percent in January, indicating a recent shift in sentiment. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Canada Standard
22-05-2025
- Business
- Canada Standard
Emcure Pharmaceuticals achieves 63% profit growth, 20% in revenue during Q4-FY25
New Delhi [India], May 22 (ANI): Pune-headquartered pharma company Emcure Pharmaceuticals on Thursday reported that its Profit After Tax or net profit in the January-March 2025 quarter grew 63 per cent to Rs 197 crore. In the same quarter of 2023-24, the pharma company's net profits were at Rs 121 crore. The company's revenue from operations rose 19.5 per cent to Rs 2,116 crore. In the year ago period, the revenue mop up was at Rs 1,771 crore. In the entire year 2024-25, the net profits rose 34.1 per cent to Rs 707 crore, and the revenue from operations rose 18.6 per cent to Rs 7,896 crore. Emcure Pharmaceuticals on Thursday announced its consolidated financial results for the quarter and year ended March 31, 2025. The quarter saw strong performance across both its domestic and international businesses, the pharma company said in a statement. Emcure's domestic business grew by 24.8 per cent, led by its women's health and cardio franchises and further aided by its new focus areas of dermatology and OTC. The international business registered a growth of 15.6 per cent led by a robust 39.3 per cent growth in the Rest of the World segment. Its Canada business continued to perform well with Mantra now fully integrated. In Europe, it recently acquired a portfolio of products and secured key regulatory approvals which will aid growth going forward, it asserted in the statement. Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., said, 'Emcure delivered a very strong performance in Q4 with all our businesses segments contributing to growth. Over the past year we have effectively executed our strategies across both Domestic and International markets.' 'On the Domestic side we have expanded our covered market and built a strong product pipeline of upcoming launches. In the International markets we are seeing approvals for our differentiated product offerings. Moving forward, while we continue to drive growth, our key priorities will be improving margins through new product launches and operating efficiencies,' Mehta added. Established in 1981, Emcure is currently present in over 70 countries. (ANI)
